Payment overview · 2025
General Payments
$233,890.75
229 reported records · 12 companies
Healthcare provider profile · identity verified
Stephen K Kidd, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAINT CLOUD, MN · NPI 1477816304
Verified facts
What the public records show
CMS Open Payments records show Stephen K Kidd, M.D. received $233,890.75 in general payments during 2025 across 229 reported records.
Edwards Lifesciences Corporation accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $96,062.94 | 41.1% | 86 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $80,641.31 | 34.5% | 59 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26,041.71 | 11.1% | 40 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $16,363.99 | 7.0% | 8 | 2025 |
| Canon Medical Informatics, Inc. | Unresolved — no canonical attribution shown | $11,850.00 | 5.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,553.66 | 1.1% | 25 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $111.72 | 0.1% | 4 | 2025 |
| Inquis Medical, Inc. | Unresolved — no canonical attribution shown | $108.77 | 0.1% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $81.41 | 0.0% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $30.59 | 0.0% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $28.86 | 0.0% | 1 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $15.79 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $108,862.50 | 30 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $99,822.50 | 32 |
| Honoraria | $11,850.00 | 1 |
| Travel and Lodging | $7,651.18 | 31 |
| Food and Beverage | $5,704.57 | 135 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $47,447.78 | 19 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $42,801.44 | 17 | 2025 |
Source payment records
|
|||||
| Sentinel Normalized: sentinel |
Device | Boston Scientific Corporation | $40,962.31 | 15 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $16,363.99 | 8 | 2025 |
Source payment records
|
|||||
| General - CT_IC Normalized: general ct ic |
Device | Boston Scientific Corporation | $12,500.00 | 4 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $9,375.00 | 3 | 2025 |
Source payment records
|
|||||
| General - Balloons Normalized: general balloons |
Device | Boston Scientific Corporation | $7,500.00 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $5,615.80 | 12 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $3,123.59 | 13 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $2,553.66 | 25 | 2025 |
Source payment records
|
|||||
| Vitalyst Normalized: vitalyst |
Device | Boston Scientific Corporation | $1,250.00 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $1,066.69 | 17 | 2025 |
Source payment records
|
|||||
| Stingray Normalized: stingray |
Device | Boston Scientific Corporation | $161.92 | 2 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $140.29 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $111.72 | 4 | 2025 |
Source payment records
|
|||||
| Aventus Normalized: aventus |
Device | Inquis Medical, Inc. | $108.77 | 1 | 2025 |
Source payment records
|
|||||
| General - Structural Heart Normalized: general structural heart |
Device | Boston Scientific Corporation | $56.39 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $30.59 | 2 | 2025 |
Source payment records
|
|||||
| Fighter Normalized: fighter |
Device | Boston Scientific Corporation | $28.92 | 2 | 2025 |
Source payment records
|
|||||
| Azurion 7 M20 Normalized: azurion 7 m20 |
Device | Philips North America LLC | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY Normalized: synergy |
Device | Boston Scientific Corporation | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Hornet 10 Normalized: hornet 10 |
Device | Boston Scientific Corporation | $11.61 | 1 | 2025 |
Source payment records
|
|||||
| MAMBA Normalized: mamba |
Device | Boston Scientific Corporation | $9.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 139 | 59 |
| Eliquis | Apixaban | 138 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 136 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 41 |
| Losartan Potassium | Losartan Potassium | 97 | 36 |
| Lisinopril | Lisinopril | 66 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 29 |
| Carvedilol | Carvedilol | 52 | 21 |
| Furosemide | Furosemide | 48 | 22 |
| Spironolactone | Spironolactone | 44 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Ezetimibe | Ezetimibe | 31 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 11 |
| Torsemide | Torsemide | 24 | 11 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233,890.75 · 229 records | Edwards Lifesciences Corporation | ALPHAVAC, AVVIGO Guidance System, Asahi Peripheral Vascular Wires, Aventus, Azurion 7 M20, COREVALVE EVOLUT R, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVOQUE, Fighter, General - Balloon Catheters, General - Balloons, General - CT_IC, General - Structural Heart, General - Therapies, General - Vascular Access, Hornet 10, MAMBA, MYNX CONTROL VENOUS, PASCAL, SAPIEN 3 Ultra RESILIA, SYNERGY, Sentinel, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Stingray, Vitalyst | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error